Recommendations
This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
Definitions and criteria for the categorisation of medicines
Legacy Merseyside
New Cheshire and Merseyside
Transition of Commissioning Policies
On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.
Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.
Documents
The Pan Mersey Area Prescribing Committee recommends the prescribing of BEMPEDOIC ACID tablets (Nilemdo®▼) and BEMPEDOIC ACID-EZETIMIBE tablets (Nustendi®▼) for primary hypercholesterolaemia or mixed dyslipidaemia in accordance with NICE TA694.
The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of DAPAGLIFLOZIN and EMPAGLIFLOZIN, following specialist recommendation, as options for treating symptomatic chronic heart failure with reduced ejection fraction in accordance with NICE TA679 and NICE TA773, and symptomatic chronic heart failure with preserved or mildly reduced ejection fraction, in accordance with NICE TA902 and TA929.
GP communication letter: SGLT2 inhibitors in heart failure
Pathway for the use of SGLT2 inhibitors in heart failure
NHS Cheshire and Merseyside APPROVED
The Pan Mersey Area Prescribing Committee recommends the prescribing of EMPAGLIFLOZIN tablets (Jardiance®) for symptomatic chronic heart failure with reduced ejection fraction, following specialist recommendation in accordance with NICE TA773.
- GP communication letter: SGLT2 inhibitors in Heart Failure with Reduced Ejection Fraction
- Pathway for the use of SGLT2 inhibitors in Heart Failure with Reduced Ejection Fraction
- EMPAGLIFLOZIN tablets (Jardiance®) for symptomatic chronic heart failure with reduced ejection fraction (Boehringer Ingelheim)
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of EVOLOCUMAB injection (Repatha SureClick®) for reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease.
The Pan Mersey Area Prescribing Committee recommends the prescribing of ICOSAPENT ETHYL capsules (Vazkepa®▼) with statin therapy, for reducing the risk of cardiovascular events in people with raised triglycerides in accordance with NICE TA805.
NHS Cheshire and Merseyside APPROVED
Ivabradine has been approved by NICE (TA 267)1 as an option for treating chronic heart failure following specialist initiation in patients with chronic, stable heart failure (NYHA class II-IV), left ventricular systolic dysfunction (LVEF 35% or less) and who are in sinus rhythm with a heart rate of 75 beats per minute or more.
The Pan Mersey Area Prescribing Committee recommends the prescribing of Rivaroxaban 2.5mg tablets (Xarelto®▼) following specialist initiation for preventing adverse outcomes after acute management of acute coronary syndrome in accordance with NICE TA335.
The Pan Mersey Area Prescribing Committee recommends the prescribing of RIVAROXABAN 2.5mg tablets (Xarelto®▼) plus aspirin, for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events, in accordance with NICE TA607.
The Pan Mersey Area Prescribing Committee recommends the prescribing of SACUBITRIL/VALSARTAN film-coated tablets (Entresto®▼) for treating symptomatic chronic heart failure following specialist initiation and in accordance with NICE TA388.
North West Strategic Clinical Network and Senate
The Pan Mersey Area Prescribing Committee recommends the prescribing of TICAGRELOR tablets (Brilique®), following specialist initiation, for the management of acute coronary syndromes in adults in accordance with NICE TA236 and for preventing atherothrombotic events after myocardial infarction in accordance with NICE TA420.